The Goal of Osmind Real-World Ketamine Analyses (ORKA)
As a Public Benefit Corporation, it is our mission to foster the development of new, effective treatments for moderate to severe mental health conditions, and to help ensure robust access to care for patients of all backgrounds. One way we work towards these goals is to advance science and clinical care through research studies and real-world evidence. ORKA (Osmind Real-world Ketamine Analyses) is a series of research studies that assess long-term patient outcomes in large samples of real-world patients undergoing ketamine therapy for depression.
The goal of ORKA is to understand the efficacy and safety of ketamine therapy as it is practiced in the community, versus the more limited scope of clinical trials. Clinical trials can only assess a specific combination of controlled parameters, whereas in the real world a variety of treatment regimens and patient characteristics intersect. It is additionally unclear how patients enrolled in prospective, randomized trials (usually in academic medical centers) compare to those seeking care in private practice. As the majority of patients receiving ketamine are treated in community practices, it is crucial to assess outcomes in these settings. Such real-world evidence is critical to establish the safety and efficacy of new treatments for patients and to obtain the necessary support of payers to ensure broad access to care.
In conjunction with some of the pioneers of ketamine therapy and leading academic partners, we are retrospectively analyzing ketamine outcomes across thousands of patients treated in community practice from 2017-2020. This study, which examines a separate patient population from ORKA-1, will supplement our published work with a larger sample size, more standardized treatment protocol, and deeper demographic data. As part of ORKA-2 we may also examine data from 2011-2017. Email us at firstname.lastname@example.org for more information.